Upstream Bio Can Beat AstraZeneca Asthma Drug: Analyst - Upstream Bio ( NASDAQ:UPB )
Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering ( IPO ) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
19 %
|
|
AMGN
|
Somewhat Bullish
|
19 %
|
|
AZN
|
Somewhat Bullish
|
19 %
|
|
UPB
|
Neutral
|
52 %
|
|
SNY
|
Neutral
|
19 %
|
